Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to Binx Health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leadership, the company grew testing volumes by double digits, established transformative industry partnerships, and led the company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017.
Prior to Good Start, Jeff co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism. From 2002 to 2009 Jeff held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.
Marc is a proven financial and operations executive who brings extensive expertise in leading financial, operational and business strategy aspects, and capital formation for both large and small, public and private healthcare and technology organizations. Prior to joining Binx Health, Marc was the COO & CFO of Good Start Genetics where he raised multiple successful rounds of capital, helped lead the impressive turnaround of the company to record business growth, and was instrumental in its ultimate sale to publicly traded Invitae.
Prior to Good Start Marc was CFO of T2 Biosystems, where he led the company’s preparation for and completion of an IPO and raised nearly $100M ($70M equity + $30M in debt); he built the finance team, implemented the necessary infrastructure and processes required of a public company, and he helped drive the commercialization of the company’s first FDA approved IVD product. Previously, Marc was CFO of Crashlytics where he oversaw the company’s acquisition by Twitter (the largest acquisition completed by Twitter at that time).
Before Crashlytics, Marc was CFO of Ivenix where he led all finance, admin, and operations functions, including raising over $8M in capital. Before that, Marc served as CFO of CHiL Semiconductor, where he oversaw growth from pre-revenue to a $20M run-rate, raised $30M in venture financing, and the ultimate acquisition of the company. Earlier in his career Marc held a number of other corporate finance positions ranging from Fortune 50 companies to high-growth startups.
As CTO, Anna plays a core leadership role for Binx Health, and is responsible for leading and coordinating all technical product development activities. Anna leads the expansion of Binx’ product roadmap, she drives the evolution of the companys’ technology vision and strategy and the exploration of novel applications of our core technology. Anna joined the company in 2007 and has extensive and demonstrated expertise in molecular product development spanning early phase feasibility, reagent formulation and integration through to late phase development and verification. Under her leadership she has driven the company’s first product to enter US clinical trial for regulatory approval. Anna spent the early part of her career working in forensic science and in genetics research before obtaining a PhD in Human Genetics from the University of Oxford.
Dr. Heller consults in Infectious Diseases at the Massachusetts Institute of Technology (MIT) Medical Department and at Massachusetts General Hospital. At MIT Medical he practiced primary care medicine and infectious diseases for 21 years and also served as Associate Medical Director. He is board certified in Internal Medicine and Infectious Disease.
Dr. Heller teaches in the Harvard-MIT Health Science and Technology (HST) program, MGH, and is Assistant Clinical Professor of Medicine, part-time, at Harvard Medical School.
Dr. Heller is a Fellow of the Infectious Disease Society of America, a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee, and has previously served as President of the Massachusetts Infectious Disease Society.
Dr. Heller received a bachelor’s degree in biology from Columbia College of Columbia University and his medical degree from SUNY-Upstate Medical University (Syracuse). He trained in internal medicine at North Shore University Hospital/ Memorial Sloan Kettering Cancer Center (Cornell) and completed a fellowship in infectious diseases at SUNY-Stony Brook. He received a master’s of public health degree from the Mailman School of Public Health of Columbia University.
Board of directors
Stanley founded EXACT Sciences and served as its CEO and Chairman until 2006. Since commercial introduction of the company’s Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry. Prior to EXACT Sciences, Stanley was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2 billion. He is the principal inventor of Cytyc’s ThinPrep Pap test, which revolutionized screening for cervical cancer and now accounts for approximately 80% of the world market for cervical cancer screening. Stanley was also the founder and CEO of SynapDx and Helicos Biosciences. Currently, Stanley serves as a director to a number of public and private medical device and diagnostics companies, and he was an instructor at MIT from 2001 to 2017. Stanley is a seasoned innovator holding 36 U.S. patents. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2013 for his work on the early detection of cancer. Stanley graduated from Cooper Union in New York City with a BS degree in electrical engineering.
Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to Binx Health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leadership, the company grew testing volumes by double digits, established transformative industry partnerships, and led the company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017. Prior to Good Start, Jeff co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism.
From 2002 to 2009 Jeff held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.
John has a background in molecular biology and significant experience in healthcare and diagnostics businesses. He co-founded Molecular Sensing Plc where he was Commercial Director and then Technical Director. Following the successful development of their DNA analysis system, he joined the US-based diagnostics company Osmetech Plc when they acquired Molecular Sensing in 2004. John led the formation of Binx Health in 2005 and was founding Chief Executive.
Jonathan was Group Finance Director of Consort Medical Plc from September 2006 to December 2007 until he took up the position of Chief Executive Officer in December 2007. Prior to joining Consort Medical Plc, Jonathan was global Head of Finance at Celltech Group Plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the life sciences industry. Jonathan joined Tissue Regenix Group Plc as a non-executive director in January 2016 and is an investor director of Binx Health Limited. Jonathan is a member of the Institute of Chartered Accountants in England and Wales.
Maxim Gorbachev has served as a member of Neothetics board of directors since July 2014.
Gorbachev is a partner at RMI Partners, LLC, the management company of Rusnano MedInvest, LLC, or RMI, LLC, a Russian-based life sciences venture capital firm, founded by RUSNANO State Corporation, which he joined in March 2013.
Prior to joining RMI Partners, from September 2012 to March 2013, Gorbachev served as Associate Director, Business Planning at JSC Sukhoi Civil Aircraft, an aerospace company.
Prior to joining JSC Sukhoi Civil Aircraft, from March 2012 to September 2012, Gorbachev acted as a consultant to various companies.
From July 2009 to February 2012, Gorbachev served as Director of Finance and Administration at UCB Pharma LLC, a pharmaceuticals company.
Prior to joining UCB Pharma, Gorbachev served as Investment Manager at Sminex, a Moscow-based private equity fund.
Gorbachev currently serves on the boards of several of RMI’s portfolio companies, including Miramar Labs.
Gorbachev earned a M.S. in applied mathematics from Lomonosov Moscow State University, a M.S. in Financial Management from The Finance University under The Government of Russian Federation and an M.B.A. from Vlerick Management School.
Florent is a Managing Director of Novartis Venture Fund (NVF) in Basel, Switzerland. Prior to joining NVF, he worked in various global leadership positions in intellectual property and transaction matters at Nestlé, Pasteur Merieux Connaught (Sanofi Pasteur), and Novartis, in Europe and North America. Florent is a Kaufmann Fellow (2012) and holds a Biotechnology Engineering Master’s Degree from France and did his diploma thesis on vaccines at GSK in Belgium. He also holds European and French patent lawyer degrees and a Masters in Private Law. Florent serves on the boards of Adicet, Anokion SA, Binx Health, Inflazome, Kanyos, Vivet, and Oculis.
Dr. Münchbach has been a Managing Partner and Investment Advisor Private Equity at BB Biotech Ventures and Bellevue Asset Management since 2004. He has been an active venture capitalist since the late 90’s investing in life science companies across all stages and types. Prior to joining Bellevue Group, he was Investment Manager at BioMed, HBM, and NMT. Dr. Münchbach’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan, and Glycart. Dr. Münchbach holds a PhD in Protein Chemistry, an MSc in Biochemistry, and a Masters in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zürich.
Samar spent six years at Amazon in various leadership roles with a focus on healthcare. In his most recent role, Samar was a product leader helping Amazon enter the prescription drug segment including its acquisition of PillPack. He has held leadership positions throughout his time at Amazon across various functions including product, operations, strategy & business development, and general management.
Prior to Amazon, Samar helped lead corporate development and strategy at Visiting Nurse Service of New York (VNSNY), helping develop the strategic roadmap for, and executing deals, including acquisitions, joint ventures, and venture capital investments. Prior to VNSNY, Samar an investment banker at Morgan Stanley. Samar holds a BS in economics and systems engineering from the United States Military Academy and an MBA from Columbia Business School.
Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland. He serves or has served on the boards of 4-Antibody (CH, now NASDAQ: AGEN), Affectis (D), Binx Health (UK), Atugen (D, now LSE:SLN Silence Therapeutics), Bioxell (I, now SIX: Cosmo Pharmaceuticals), Cardior (D), Cellerix (E, now NYSE Euronext: Tigenix), IDEA (D), Morphochem (D, now: Biovertis), Idenix (USA, then NASDAQ: IDIX, now Merck), Luxendo (D, now Bruker Corp), Nouscom (CH), Okairos (CH, now: GSK), Omrix Biopharmaceuticals (NYSE: OMRI, then J&J), Scion Pharmaceuticals (USA), t.Breeders (NASDAQ: Viacell, then NYSE:PKI), and U3 Pharma (D, now: Daiichi-Sankyo).
In addition, he serves pro bono on the boards of various tech transfer organizations such as Ascenion, AWS, or the Life Science Incubator. Joachim obtained a master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature.
Jihua has served on the board of directors of since January 2017. As a member of the first generation of pioneers in establishing private biotechnology companies in China, Jihua founded Guangzhou Wondfo Biotech Co., Ltd, in 1992, and served as the CEO until June 2016. After leading the company to IPO in 2015, Jihua has been appointed Chairman of the Board since July 2016. Since 2009, Jihua has been the President of Wondfo USA, where she oversees global strategic planning. She has extensive experience in IVD technology and healthcare business. Jihua received a B.S. from Hunan Medical University and M.S. from State Key Laboratory of Enzyme Engineering of Jilin University. She worked as a visiting scholar at Harvard Medical School in 2000.
Zeev is Vice President of Venture Investments for Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and joined in 1999. He is based out of offices in Israel and Belgium. Zeev’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd.
While operating this consultant business for medical device and pharmaceutical start-up companies, Zeev initiated contacts with various Johnson & Johnson companies. Zeev holds a Bachelor of Science from Hebrew University of Jerusalem and a Master of Business Administration in Marketing and Finance from Tel Aviv University. He is fluent in Hebrew, English, and Arabic.